** Shares of drug developer Tango Therapeutics TNGX.O rise 34.7% to $27.3

** Co's experimental drug combination showed strong early results in a small study of patients with advanced pancreatic cancer

** Co plans to advance the drug into late-stage studies

** Co's drug vopimetostat, in combination with Revolution Medicines' RVMD.O daraxonrasib, shrank tumor in 11 of 12 patients with a type of pancreatic cancer that was previously treated

** For the late-stage trial, Tango plans to test the combination treatment in first-line pancreatic cancer patients with a genetic mutation known as MTAP deletion, pending discussions with regulators

** "We expect that TNGX shares could be up as much as 2X on these data given the size of the opportunity, and the unprecedented efficacy, confirming synergies between the classes," says Leerink Partners

** Including session moves, stock more than tripled YTD